Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03467347 · ClinicalTrials.gov registry record · Phase 1

PK Study of 90-Day Use of Vaginal Rings Containing Dapivirine and Levonorgestrel

A Phase 1 study, sponsored by International Partnership for Microbicides.

Completed
Registry status
Phase 1
Development phase
25
Enrollment target

NCT03467347 is a Phase 1 study that has completed, run by International Partnership for Microbicides. The registered enrollment target is 25 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03467347, a Phase 1 study, has completed, sponsored by International Partnership for Microbicides.

COMPLETED
Registry status
Phase 1
Development phase
25 participants
Enrollment target

Study Summary

This is a Phase I single-center, two-arm, open-label, randomized study in healthy HIV-negative women to evaluate the pharmacokinetics, safety, and bleeding patterns associated with 90-day use of matrix vaginal rings containing 200 mg Dapivirine and 320 mg Levonorgestrel.

Interventions

  • DRUG VR: 200 mg DPV + 320 mg LNG

Trial Details

FieldValue
Enrollment Target 25 participants
Start Date 2018-07-17
Est. Completion 2019-10-07
Phase Phase 1

What the Registry Record Tells You About NCT03467347

The ClinicalTrials.gov registry entry for NCT03467347 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is International Partnership for Microbicides, which has 14 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which VR: 200 mg DPV + 320 mg LNG is the first listed.

NCT03467347 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT03467347 about?

NCT03467347 is a clinical study titled "PK Study of 90-Day Use of Vaginal Rings Containing Dapivirine and Levonorgestrel". This is a Phase I single-center, two-arm, open-label, randomized study in healthy HIV-negative women to evaluate the pharmacokinetics, safety, and bleeding patterns associated with 90-day use of matrix vaginal rings containing 200 mg Dapivirine and 320 mg Levonorgestrel.

What is the current status of trial NCT03467347?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 25 participants. The study started on 2018-07-17. Estimated completion is 2019-10-07.

What interventions are being tested in trial NCT03467347?

The interventions under investigation include: VR: 200 mg DPV + 320 mg LNG (DRUG).

Who is sponsoring clinical trial NCT03467347?

This trial is sponsored by International Partnership for Microbicides, which has 14 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.